AI-Powered Embryo Assessment from Alife Health Receives FDA Clearance

The announcement of its product, Embryo Predict, has received clearance from the U.S. Food and Drug Administration (FDA). This covers the use of Embryo Predict to help fertility specialists to evaluate and select embryos for transfer during in vitro fertilization (IVF), one of the most consequential decisions in the IVF process. 

 The U.S. is undergoing an average of three cycles before a successful pregnancy, whereas IVF is the most emotionally and financially demanding medical journey a person can take, including choosing which embryo to transfer. Researchers have discovered a 34.6% disagreement rate among fertility specialists selecting the top embryo for transfer, rising to 44% when patients had three or more embryos to choose from. 

According to Towards Healthcare, the U.S. fertility diagnostic market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 1.55 billion in 2026 to approximately USD 3.33 billion by 2035, representing a compound annual growth rate (CAGR) of 8.9% from 2026 to 2035. Growth is driven by the delayed childbirth and rising median age of women at first pregnancy, resulting in a natural decline in reproductive capacity and an increased need for diagnostic screening to assess ovarian reserve and hormone levels. 

About Alife Health

The company is based in San Francisco, California. Market growth is utilised by AI to standardize clinical decision-making, like optimizing ovarian stimulation, and improve IVF success rates. This helps to boost clinical efficiency, reduce medication costs, and helps manage the high demand for assisted reproductive technology (ART) across the country. It helps to transform reproductive healthcare. 

The main purpose of the company is to bring consistency, efficiency, and data-driven decision support to every stage of the IVF process. The company also offers FDA-cleared and microscope-integrated tools for embryo assessment and clinic optimization. Alife targets the inefficiencies, subjectivity, and success rates that have historically challenged U.S. reproductive medicine. 

It also develops AI tools for IVF clinicians and labs, including Embryo Predict, its AI-powered adjunctive embryo selection tool; Schedule Predict, a scheduling optimization tool; and Success Predictor, a patient-facing family planning tool. 

A recent report by Towards Healthcare highlights that the ​​U.S. fertility diagnostic market is witnessing growth due to rising demand for IVF and infertility rates climbing in the U.S., as well as increased reliance on Assisted Reproductive Technologies (ART). Alife targets the inefficiencies, subjectivity, and success rates that have historically challenged U.S. reproductive medicine.